Where Can I Buy NAD+ 500mg?
September 9, 2026
Researchers looking for NAD+ 500mg for laboratory research can purchase it from Neuro Peptides. NAD+,
Retatrutide (LY3437943), developed by Eli Lilly and Company, is an investigational peptide currently not approved for human consumption and is under investigation. It works by targeting three hormone receptors:
This unique triple-action mechanism makes it different from the rest of the peptides that have been developed for the treatment of various metabolic disorders.
There have been several successful trials conducted on retatrutide’s clinical performance, with the most prominent one published in the New England Journal of Medicine.
According to the article, a phase 2 clinical trial that was completed in 2023 assessed the efficacy and safety of once-weekly subcutaneous injections of retatrutide in adults with obesity. The results revealed that all doses of the medication had led to considerable weight reduction compared to the placebo group after 48 weeks of treatment. The gastrointestinal adverse events were the most commonly reported side effects.
The following phase 3 clinical trials have also been completed in July 2026, with Eli Lilly announcing top-line data from the TRIUMPH trials and preparing to submit a biologics license application to the Food and Drug Administration (FDA) in the first quarter of 2027. Thus, it can be concluded that retatrutide is still an investigational pharmaceutical compound that has not received regulatory approval.
This guide provides detailed information on retatrutide, including its mechanism of action, the findings from the preclinical and clinical studies and latest Retatrutide research, and its current status in the medical community. It can be noted that the majority of the collected research data is based on clinical performance rather than an established treatment approach.
| Property | Details |
| Generic Name | Retatrutide |
| Development Code | LY3437943 |
| Drug Class | Triple hormone receptor agonist |
| Major Target | GIP, GLP-1, and glucagon receptors |
| Developer | Eli Lilly and Company |
| Molecular Type | Synthetic peptide |
| CAS number | 2381089-83-2 |
| PubChem ID | 171390338 |
| Status | Investigation (RUO) |
The IUPHAR/BPS Guide to Pharmacology lists retatrutide as a peptide and thus confirms its CAS Registry Number and PubChem identifier.
Retatrutide has advanced from initial pharmacological investigations into large-scale clinical examinations. In particular, a phase 2 obesity trial published in the NEJM in 2023 assessed the drug’s efficacy over a 48-week treatment period, establishing key information about the dose-dependent nature of its mechanism and impact.
It is vital to recognize that retatrutide is experimental, and the results of clinical studies cannot be used to assert the safety or effectiveness of an unapproved pharmaceutical preparation.
The mode of action of Retatrutide is triple-receptor agonism, which activates glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR).
According to a study carried out by Coskun et al. in 2022 in Cell Metabolism, the compound LY3437943 was characterized during its discovery and initial clinical development. The study revealed that retatrutide activates all three receptors. Laboratory tests revealed that retatrutide has balanced activity on the glucagon and GLP-1 receptors, while it has stronger activity on the GIP receptor. Studies done on obese mice have shown that the inclusion of GCGR activity results in increased energy expenditure along with decreased food intake.
The GLP-1 receptor belongs to the incretin pathway and plays a significant role in glucose regulation and appetite signaling. GLP-1 receptor activation may lead to an increased insulin secretory function that depends on the level of glucose and may affect appetite-related signals.
The GLP-1 receptor activity of retatrutide represents one aspect of the metabolic pathway. In the Phase 2 obesity study in 2023 published in NEJM, retatrutide was identified as an agonist of the GLP-1, GIP, and glucagon receptors.
GIP is one more incretin hormone involved in the regulation of glucose-dependent insulin release and metabolism. Activation of the GIP receptor is one more way in which retatrutide exerts its biological actions.
According to the results obtained in the Cell Metabolism study conducted by Coskun et al., retatrutide was more active at the human GIP receptor compared with the human GLP-1 and glucagon receptors in vitro.
There is also evidence regarding the biological activity of this pathway from human studies. Thus, according to the Phase 1b randomized clinical trial performed by Urva et al. and published in The Lancet, the effects of LY3437943 were investigated in adults with type 2 diabetes.
The third piece of the puzzle is the activation of glucagon receptors. Glucagon is an essential regulator of glucose metabolism in the liver and overall energy metabolism. Moreover, glucagon signaling was studied by researchers as it has a potential effect on energy expenditure and substrate utilization.
This evidence is very useful for understanding the mechanism in question because the 2022 research conducted in Cell Metabolism revealed that in obese mice, the weight loss caused by retatrutide was related to lower caloric consumption due to the activity of GIP and GLP-1 receptors as well as higher energy expenditure due to glucagon receptor activity.
The main scientific interest of retatrutide is that it targets GIP, GLP-1, and glucagon signaling rather than just one pathway. The developers proposed that the combination of these pathways may affect both energy intake and energy expenditure.
The preliminary results are consistent with biological rationale, but do not prove that all proposed mechanisms have equal effect in humans. Thus, the researchers moved from laboratory and animal studies into controlled human trials.
The biological activity of retatrutide was further supported by clinical data from a Phase 2 obesity study by Jastreboff et al. published in The New England Journal of Medicine in 2023. Retatrutide’s triple-receptor pharmacology was established in the clinic in a randomized, double-blind trial in which multiple weekly doses were tested over 48 weeks.
While retatrutide has advanced from early pharmacology research to large phase 3 trials, the evidence pertains to clinical findings on weight loss, glucose regulation, metabolic health indicators, and tolerability. It is too early to conclude the medication as an established treatment.
A 2022 phase 1b, randomized, double-blind, placebo-controlled trial in The Lancet evaluated LY3437943 for use in participants with type 2 diabetes and explored the drug’s pharmacokinetics, glucose-lowering function, impact on body weight, and tolerability. The article revealed a dose-dependent change in weight and glycemic indices and identified gastrointestinal side effects as the most frequent adverse events. This early-stage study provided initial clinical evidence on the drug’s potential in humans.
The most informative study on retatrutide so far comes from a phase 2, randomized, double-blind, placebo-controlled trial published in NEJM. This 2023 study enrolled 338 adults with obesity or overweight with an additional weight-related condition in a 48-week intervention.
According to the published findings, the least-squares mean changes in body weight from baseline were – 8.7% for the 1 mg group, – 11.8% for the 3 mg group, – 16.3% for the 6 mg group, – 21.7% for the 9 mg group, – 23.6% for the 12 mg group, versus – 2.1% for the placebo. The greatest proportion of patients who achieved at least a 15% decrease in weight was observed in the 12 mg group (44.3%). The most common adverse events were treatment-emergent gastrointestinal disorders such as nausea, diarrhea, and vomiting, which were mostly dose-dependent. The incidence of gastrointestinal adverse events decreased when the starting dose was between 3 mg and 6 mg. Additionally, the treatment groups showed consistent and clinically relevant increases in heart rate from baseline that peaked at week 24 before declining.
The evidence about retatrutide’s clinical effectiveness comes from the TRIUMPH phase 3 trials. According to Eli Lilly’s 2026 press release, the company has reported positive top-line results from TRIUMPH-1, one of the key studies in the phase 3 program.
Regarding TRIUMPH-1 findings, the trial’s participants who received 12 mg of retatrutide had recorded a 28.3% average weight reduction at week 80. TRIUMPH-1 was a study of patients with obesity or overweight with at least one weight-related condition without diabetes.
In July 2026, Lilly announced similar positive results from TRIUMPH-2 and TRIUMPH-3. While TRIUMPH-2 was an obesity study in patients with type 2 diabetes, TRIUMPH-3 was a trial of patients with severe obesity and established cardiovascular disease. Across all three trials, the highest dose of retatrutide resulted in the highest average percentage of weight reduction, with 20.8% and 22.6% in TRIUMPH-2 and TRIUMPH-3, respectively.
The research findings suggest that retatrutide has meaningful clinical efficacy in reducing body weight with notable tolerability concerns. However, it is important to note that these are top-line data published as press releases; the final peer-reviewed versions of these articles may provide more context and detail about the findings.
The clinical research on retatrutide shows that the drug has demonstrable physiological efficacy, targeting three receptors while causing substantial decreases in body weight and glycated hemoglobin in clinical trials.
The evidence continues to grow, with the body of research providing consistent findings as triatrutide progresses from phase 1 trials to phase 3 studies.
That said, it is too early to conclude the medication based on the currently available evidence. More research is needed, and regulatory agencies have yet to review and approve the drug for clinical use.
Retatrutide is different from semaglutide and tirzepatide mainly through its three-receptor mechanism. Semaglutide activates only the GLP-1 receptor, while tirzepatide activates both the GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity to these two incretin pathways.
| Characteristics | Retatrutide | Semaglutide | Tirzepatide |
| Target | GIP, GLP-1, glucagon | GLP-1 | GIP, GLP-1 |
| Receptor Activity | Triple agonist | GLP-1 receptor agonist | Dual GIP/GLP-1 agonist |
| Status | Investigational | Approved medication | Approved medication |
| Clinical Research | Phase 3 trials | Extensive Phase 3 evidence | Extensive Phase 3 evidence |
| Activity Glucagon Receptor | Yes | No | No |
| Major Research Interest | Combined metabolic signaling | GLP-1 signaling | Combined GIP and GLP-1 signaling |
Safety and tolerability continue to be important areas of research with retatrutide. Clinical trials have reported several adverse events, with gastrointestinal symptoms among the most common. Retatrutide is investigational, and the current evidence does not support long-term safety with widespread use.
In their 2023 Phase 2 obesity trial published in the New England Journal of Medicine, Jastreboff et al. reported that nausea, diarrhea, and vomiting were the most frequent adverse events. They also noted that GI events tended to increase in frequency with increasing doses of retatrutide.
The same study also reported that some participants stopped treatment because of adverse events. They also found an increase in heart rate during treatment, with an average increase that peaked at approximately week 24 and then declined later in the study.
Another Phase 1b study published in The Lancet by Urva et al assessed the safety and tolerability of LY3437943 in adults with type 2 diabetes. Adverse events, vital signs, laboratory measurements, and other clinical parameters were monitored by investigators during the dose-escalation study.
Retatrutide is being developed in Phase 3, and researchers are still evaluating its long-term safety profile. These studies are particularly important because larger participant populations and longer follow-up periods can identify safety patterns that early trials may not detect.
Current clinical studies include:
It is important to differentiate between clinical-trial evidence and research-product use. Trial results describe outcomes under controlled conditions with specific formulations, protocols, doses, and monitoring systems. They do not establish that an unapproved retatrutide research product is safe or appropriate for human use.
For this reason, retatrutide should continue to be described as an investigational compound until regulatory authorities complete their review.
No. Retatrutide is not FDA-approved as of August 2026. It is currently being developed as an investigational drug by Eli Lilly. Eli Lilly announced positive outcomes from various Phase 3 studies conducted in 2026; however, positive clinical trial results do not automatically lead to drug approval.
Eli Lilly noted in July 2026 that it plans to file for a BLA with the FDA in the first quarter of 2027. Hence, this means that the process of drug approval is still ongoing.
According to the FDA, retatrutide is not an FDA-approved drug and has not been established as safe and effective for the treatment of any disease condition. Moreover, according to the FDA, retatrutide may not be compounded under federal law.
Such a difference is critical for research laboratories. Results from clinical trials are sources of useful data on the pharmacology, effectiveness, and safety of retatrutide. This does not imply that retatrutide in commercial preparations has the same formulation or clinical status as the retatrutide used during Lilly-sponsored trials.
Therefore, when preparing research-related material, one should refer to retatrutide as an investigational drug.
Researchers working with retatrutide should focus on:
These factors are useful for researchers to understand the material used in an experiment and support better reproducibility across studies.
Retatrutide, or LY3437943, is an experimental peptide made by Eli Lilly. It works to activate GIP, GLP-1, and glucagon receptors. The research into triple receptor activation investigates its effects on metabolism, weight loss, and glucose management.
Retatrutide works by activating the GIP, GLP-1, and glucagon receptors in one molecule. The combined effect may be related to appetite, glucose management, energy expenditure, and metabolism. The 2022 Cell Metabolism study by Coskun et al. gave important proof of this triple receptor effect.
Retatrutide is not a selective GLP-1 receptor agonist. It is a triple receptor agonist that acts on the GIP, GLP-1, and glucagon receptors.
No. In contrast to retatrutide, which acts on GIP, GLP-1, and glucagon receptors, tirzepatide acts on GIP and GLP-1 receptors only.
There is evidence that retatrutide reduces body weight and shows favorable effects in glucose metabolism in a dose-dependent manner. For example, according to a Phase 2 clinical trial of 2023 published in the New England Journal of Medicine, retatrutide was found to reduce body weight in adults with obesity over 48 weeks.
No. Retatrutide is still an experimental agent and is not FDA approved. According to Eli Lilly, the company plans to submit a Biologics License Application (BLA) for retatrutide to the FDA in 2027.
Nausea, diarrhea, and vomiting were among the most frequently reported adverse events in the Phase 2 obesity trial. Gastrointestinal events generally occurred more often at higher doses.
Retatrutide is being studied in the lab and in clinical trials as an investigational compound. Products not marketed through approved clinical programs should not be presented as FDA-approved drugs or as being similar to clinical-trial formulations.
However, if you are planning to buy it for research purposes, you can buy retatrutide at Neuro Peptides.
Retatrutide (LY3437943) is a highly relevant topic of discussion for metabolic research due to its activity on GIP, GLP-1, and glucagon receptors. Some preclinical experiments and clinical trials in humans have been conducted that show promising results in terms of changes in body weight and glucose levels.
This research has progressed from Phase 1 and Phase 2 trials to larger Phase 3 trials. Yet, retatrutide is still investigational and is not FDA-approved. Hence, it is necessary to differentiate between the results of clinical trials and commercially available research products.
Regarding research laboratories, proper handling of reagents such as correct identity, analysis, certification, storage, and use in research is still required. With more Phase 3 trials coming out and an ongoing regulatory process, scientific knowledge on retatrutide will be expanding.
Researchers who are interested in studying retatrutide and other research peptides can obtain the appropriate research materials via Neuro Peptides.
Researchers looking for NAD+ 500mg for laboratory research can purchase it from Neuro Peptides. NAD+,
Mitochondria have long been understood as essential sites of cell energy production; however, accumulating evidence
Researchers looking for Retatrutide 10mg for laboratory research can find this research compound at NeuroPeptides.
MOTS-C is a 16-amino-acid mitochondrial-derived peptide (MDP) that has attracted growing interest in research on
MOTS-C is a mitochondrial-derived peptide (MDP) that has been extensively investigated in the context of
MOTS-C is one of the latest mitochondrial-derived research peptides being investigated with growing interest in